Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Syrrx’s Structural Proteomics At Heart Of Pharmacia Alliance

Jan. 25, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Jan. 9, 2002

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...